[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-373596-105":59,"doc-detail-373596-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","peripheral-blood-proteome-biomarkers-distinguish-immunosuppressive-features-of-cancer-progression","Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression","","Immune status critically shapes cancer progression and therapeutic response. This study aimed to identify plasma proteome changes linked to immunosuppressive cancer and biomarkers that predict systemic immunosuppression. Using syngeneic breast tumor mouse models, plasma from naïve and early-/late-stage tumor-bearing mice was analyzed by LC–MS. 4T1 tumors induced systemic immunosuppression with MDSCs as early as day 7, unlike 67NR.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/peripheral-blood-proteome-biomarkers-distinguish-immunosuppressive-features-of-cancer-progression/373596/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/peripheral-blood-proteome-biomarkers-distinguish-immunosuppressive-features-of-cancer-progression/373596.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary goal of the study?","Question",{"text":112,"@type":113},"To identify plasma proteome changes associated with immunosuppressive cancer progression and to find potential biomarkers predicting systemic immunosuppression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the plasma samples collected and analyzed?",{"text":117,"@type":113},"Plasma samples were collected from naïve and early-/late-stage tumor-bearing syngeneic breast tumor mouse models and analyzed using liquid chromatography–mass spectrometry (LC–MS).",{"name":119,"@type":110,"acceptedAnswer":120},"Which mouse model showed systemic immunosuppression and what immune feature characterized it?",{"text":121,"@type":113},"4T1-bearing mice showed systemic immunosuppression, characterized by significant generation of myeloid-derived suppressor cells (MDSCs) as early as 7 days after tumor implantation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},373596,1790918177,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression Yeon Ji Park 1,2, Jae Won Oh3, Hyewon Chung4, Jung Won Kwon4, Yi Rang Na 1,5,6 , Kwang Pyo Kim3,7  and Seung Hyeok Seok2,4,5   \n1 Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea  \n2 Cancer Research Institute, Seoul National University, Seoul, Republic of Korea  \n3 Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea  \n4 Macrophage Lab, Department of Microbiology and Immunology, and Institute of Endemic Disease, Seoul National University College of Medicine, Seoul, Republic of Korea  \n5 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea  \n6 Immunology Core Facility, Department of Translational Research Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea  \n7 Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, Republic of Korea  \nKeywords  \nbiomarker; immunosuppressive cancer; myeloid-derived suppressor cells; plasma; proteomics  \nCorrespondence  \nY. R. Na, Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea  \nTel: +82 2 2072 4490  \nE-mail: [yirangna@snu.ac.kr](yirangna@snu.ac.kr)and  \nK. P. Kim, Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea  \nE-mail: [kimkp@khu.ac.kr](kimkp@khu.ac.kr)and  \nS. H. Seok, Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea  \nTel: +82 2 740 8302  \nE-mail: [lamseok@snu.ac.kr](lamseok@snu.ac.kr)  \nYeon Ji Park and Jae Won Oh are first author.  \nImmune status critically affects cancer progression and therapy responses. This study aimed to identify plasma proteome changes in immunosuppressive cancer and potential biomarkers predicting systemic immunosuppression. Mouse models of syngeneic breast tumors (benign 67NR and malignant 4T1) were used to collect plasma samples. Plasma samples from naive mice and both early- and late-stage tumor-bearing mice were subjected to liquid chromatography–mass spectrometry (LC–MS) analysis. 4T1-bearing mice showed systemic immunosuppression characterized by significant generation of myeloid-derived suppressor cells (MDSCs) as early as 7 days after tumor implantation, unlike 67NR tumors. LC–MS identified 1086 proteins across the five experimental groups, with 27 proteins showing group-specific expression in 4T1 blood compared with 67NR blood. Immune-related proteins osteopontin, lactotransferrin, calreticulin, and peroxiredoxin 2 were selected as potential biomarkers of MDSC-producing breast cancer. These markers were expressed in cancer cells or MDSC in the 4T1 model, and osteopontin and peroxiredoxin 2 were associated with low survival probability and high recurrence inpatients with triple-negative breast cancer. Our findings suggest that MDSC-producing immunosuppressive cancers have unique plasma proteomes, offering additional insights into cancer immune status.  \nAbbreviations  \nBRCA, breast cancer; CARL, calreticulin; DFS, disease-free survival; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; FUSCC, Fudan University Shanghai Cancer Center; G-MDSC, granulocytic myeloid-derived suppressor cell; HER2, human epidermal growth factor receptor 2; LC–MS, liquid chromatography–mass spectrometry; LTF, lactotransferrin; MDSC, myeloid-derived suppressor cell;  \nM-MDSC, monocytic myeloid-derived suppressor cell; PBS, phosphate-buffered saline; PMN, polymorphonuclear; PRDX2, peroxiredoxin 2; RFD, recurrence-free survival; SPP1, secreted phosphoprotein 1; TCGA, The Cancer Genome Atlas; TME, tumor microenvironment; TMT, tandem mass tag; TNBC, triple-negative breast cancer.  \nMolec","cbCaiowYOP2F4QmP","https://ap.wps.com/l/cbCaiowYOP2F4QmP","pdf",2572457,16,"English","# Introduction\n## Systemic immune perturbations in tumor progression\n## Peripheral immune involvement and MDSC expansion","[{\"question\":\"What was the primary goal of the study?\",\"answer\":\"To identify plasma proteome changes associated with immunosuppressive cancer progression and to find potential biomarkers predicting systemic immunosuppression.\"},{\"question\":\"How were the plasma samples collected and analyzed?\",\"answer\":\"Plasma samples were collected from naïve and early-/late-stage tumor-bearing syngeneic breast tumor mouse models and analyzed using liquid chromatography–mass spectrometry (LC–MS).\"},{\"question\":\"Which mouse model showed systemic immunosuppression and what immune feature characterized it?\",\"answer\":\"4T1-bearing mice showed systemic immunosuppression, characterized by significant generation of myeloid-derived suppressor cells (MDSCs) as early as 7 days after tumor implantation.\"}]","Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression | PDF",1790199983]